Boston Scientific Corp (BSX)
Healthcare
Medical Devices
46.70 $
+1.6%
vs. previous close
Closing price · As of: 31. Jul 2026
| Tick rows to compare them in a chart (up to 4) | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34,043 | 35,136 | 36,669 | 37,108 | 38,078 | 39,395 | 40,140 | 41,559 | 42,707 | 43,673 | 44,351 | – | |
| 6,504 | 6,514 | 8,185 | 8,991 | 8,761 | 6,920 | 7,335 | 7,121 | 8,035 | 8,794 | 8,684 | – | |
| 952 | 865 | 2,329 | 2,913 | 2,502 | 414 | 725 | 534 | 1,275 | 2,045 | 1,524 | – | |
| 952 | 865 | 2,329 | 2,913 | 2,502 | 414 | 725 | 534 | 1,275 | 2,045 | 1,524 | – | |
| 2,101 | 2,228 | 2,304 | 2,400 | 2,501 | 2,558 | 2,693 | 2,815 | 2,828 | 2,926 | 3,027 | – | |
| 2,404 | 2,484 | 2,561 | 2,608 | 2,753 | 2,810 | 2,867 | 2,861 | 2,921 | 2,944 | 3,117 | – | |
| 3,081 | – | – | – | 3,498 | 3,743 | 3,837 | 3,953 | 4,290 | 4,501 | – | – | |
| 13,608 | 14,387 | 14,361 | 14,397 | 15,033 | 17,089 | 17,340 | 18,076 | 18,214 | 18,282 | 18,536 | – | |
| 5,850 | 6,003 | 5,837 | 5,417 | 5,754 | 6,684 | 6,565 | 7,259 | 7,161 | 7,019 | 7,060 | – | |
| 14,914 | 15,606 | 16,501 | 16,498 | 17,122 | 17,392 | 17,694 | 18,906 | 19,077 | 19,201 | 18,247 | – | |
| 4,579 | 4,933 | 4,916 | 5,576 | 5,910 | 6,399 | 5,058 | 5,190 | 5,328 | 5,439 | 4,571 | – | |
| 513 | 531 | 1,085 | 1,580 | 1,652 | 1,778 | 777 | 480 | 483 | 389 | 41 | – | |
| 929 | 942 | 921 | 906 | 907 | 960 | 1,004 | 962 | 1,002 | 1,144 | 1,141 | – | |
| 8,386 | 8,566 | 9,530 | 8,987 | 9,229 | 8,842 | 10,406 | 10,981 | 10,993 | 11,137 | 10,864 | – | |
| 18,885 | 19,281 | 19,925 | 20,371 | 20,708 | 21,770 | 22,212 | 22,418 | 23,395 | 24,233 | 25,864 | – | |
| 315 | 819 | 1,314 | 1,639 | 2,107 | 2,673 | 3,347 | 4,144 | 4,899 | 5,571 | 6,912 | – | |
| 1,475 | 1,477 | 1,482 | 1,484 | 1,487 | 1,490 | 1,493 | 1,493 | 1,496 | 1,496 | 1,495 | 1,485 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.